Cilostazol and outcome in outpatients with peripheral artery disease.

Background: Cilostazol increases the walking distance in patients with intermittent claudication, but there is scarce evidence of any effect on the risk for subsequent ischemic events, bleeding or death.

Patients And Methods: We used data from the FRENA Registry to compare the clinical outcome in stable outpatients with intermittent claudication, according to the use of cilostazol.

Results: As of January 2013, 1,317 patients with intermittent claudication were recruited in FRENA, of whom 191 (14.